Cellivery Therapeutics, Inc.

As of September 30, 2024, Cellivery Therapeutics, Inc. has 37.14M shares outstanding.

These figures are as of September 30, 2024. The EV/Sales ratio of 4.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of September 30, 2024, Cellivery Therapeutics, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -22.94, reflecting losses generated across the asset base.

As of the close on March 23, 2023, Cellivery Therapeutics, Inc.'s stock has declined approximately 57.11% over the past 52 weeks. The 50-day moving average sits at 11,492.60, while the 200-day moving average is 12,832.53.

Over the twelve months ended September 30, 2024, Cellivery Therapeutics, Inc. posted a gross margin of 0.44, reflecting its pricing power and cost economics. The operating margin of -57.64 and net profit margin of -24.97 provide insight into operational efficiency.

Cellivery Therapeutics, Inc.'s most recent stock split took place on July 25, 2022 with a 1:2 split ratio.

As of September 30, 2024, Cellivery Therapeutics, Inc. has an Altman Z-Score of -3.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.